Brincidofovir (BCV) has broad-spectrum in vitro activity against dsDNA viruses, including
smallpox, and is being developed as a treatment for smallpox as well as infections caused …

Smallpox, caused by Variola virus (VARV), was eradicated in 1980; however, VARV
bioterrorist threats still exist, necessitating readily available therapeutics. Current …

Orthopoxviruses continue to pose a significant threat to the population as potential agents of
bioterrorism. An intentional release of natural or engineered variola virus (VARV) or …

Abstract Brincidofovir (BCV, CMX001) is an orally available, long-acting, broad-spectrum
antiviral that has been evaluated in healthy subjects in Phase I studies and in hematopoietic …

The development and approval of brincidofovir for the treatment of smallpox, a disease that
was eradicated from the world over 40 years ago, has resulted in the second antiviral …

Smallpox (variola) virus is considered a Category A bioterrorism agent due to its ability to
spread rapidly and the high morbidity and mortality rates associated with infection. Current …

The monkeypox disease (MPX) outbreak of 2022 has been reported in more than one
hundred countries and is becoming a global concern. Unfortunately, only a few treatments …

CMX001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy) propan-
1-ol to cidofovir (CDV), is being developed as a treatment for smallpox. CMX001 has …

In the event of a bioterror attack with variola virus (smallpox), exposure may only be
identified following onset of fever. To determine if antiviral therapy with brincidofovir (BCV; …

Recently, there has been renewed interest in finding orally active drugs against smallpox.
Cidofovir (CDV) given by parenteral injection has been shown to protect against lethal …